The Employees State Insurance Corporation (ESIC) on November 09, 2026, notified regarding the revised Specifications, Brand Name, and Rate of Inactivated Influenza Vaccine under Rate Contract RC-156.
It has revised the specifications, brand name, and rate of approved Item No. 2228 under Rate Contract RC-156 of M/s. Zydus Lifesciences Limited for Inactivated Influenza Vaccine, pursuant to the latest WHO recommendations for influenza vaccination in the Northern Hemisphere. The existing tetravalent vaccine, Vaxiflu-4™, has been replaced with the trivalent vaccine, Vaxiflu™, and the ratehas been reduced from ₹775 to ₹725 per 0.5 ml PFS, plus GST. The amendment, issued at the firm's request, will remain effective until the expiry of DGESIC RC-156 or finalisation of fresh Tender Enquiry No. TE-172, whichever is earlier. The supplied vaccine shall continue to comply with the approved composition and strength under the rate contract and applicable standards under the Drugs and Cosmetics Act and amendments thereto.
[Notification No. - U-25/12/154-158/Amendment/Packing/2024-Med.V (E:869597)/339]
